Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL6918924 | 0.98 | HTR2A (0.34) | HTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL7936356 | 0.97 | HTR6 (0.32) | HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL216460 | 0.97 | HTR6 (0.32) | HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL29479964 | 0.97 | HTR6 (0.32) | HTR2AHTR6SIGMAR1 | |
| SCHEMBL6917207 | 0.97 | HTR6 (0.32) | HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6914377 | 0.95 | HTR6 (0.31) | HTR2AHTR6 | |
| SCHEMBL6916948 | 0.93 | SIGMAR1 (0.31) | HTR2AHTR6SIGMAR1 | |
| Hydrochloric Acid SCHEMBL6916559 | 0.92 | SIGMAR1 (0.31) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL216044 | 0.80 | SIGMAR1 (0.31) | HTR2AHTR6SIGMAR1 | |
| Bromide SCHEMBL6910531 | 0.79 | HTR2A (0.37) | HTR2AHTR6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0927201-B1 | CATALYST SYSTEM FOR (CO)POLYMERIZATION OF OLEFINS AND PROCESS FOR THE PREPARATION OF OLEFIN (CO)POLYMERS USING THE CATALYST SYSTEM | HYUNDAI PETROCHEMICAL CO LTD (KR) | 2004-04-14 | — | — | EP | disclosed |
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | THOMPSON LORIN A (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0530908-B2 | Process for the preparation of a bridged metallocene compound as well as a catalyst component and a process for the polymerization of olefins | DSM NV (NL) | 2003-06-04 | — | — | EP | disclosed |
| EP-0530908-B1 | Process for the preparation of a bridged metallocene compound as well as a catalyst component and a process for the polymerization of olefins | DSM NV (NL) | 1999-04-21 | — | — | EP | disclosed |
| US-5646083-A | Process for the preparation of a bridged metallocene compound as well as a catalyst component and a process for the polymerization of olefins | DSM N.V. (NL) | 1997-07-08 | — | — | US | disclosed |
| EP-0530908-A1 | Process for the preparation of a bridged metallocene compound as well as a catalyst component and a process for the polymerization of olefins | DSM N.V. (NL) | 1993-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130251-A1 | Amino lactam sulfonamides as inhibitors of A-beta protein production | APP, APH1A, BACE1 | HTR2A 2622/4885HTR6 4372/4885SIGMAR1 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.